The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
that's one of the things that also makes me optimistic about rapamycin is we already know that it hits the hallmarks of aging you know and it also seems to be effective in these Alzheimer's disease models so that makes me think that it's acting and it was sort of a more fundamental level
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
but I think rapamycin is going to impact epigenetic changes with aging and that's gets back to the complexity of the downstream part which we haven't even touched on all the different things that empor complex one and mtor complex 2 regulate
I think there will be a very strong case that these drugs are acting by slowing the aging process and delaying maybe not quite all but maybe all of the um aspects of Aging that make people unhappy about getting older
If you take an intervention like rapamy that slows aging, it can impact all of the hallmarks. Um, and so I don't really I think those are like outputs or ways you can look at aging, but they're not the nobody is really just targeted.
So, if you take an intervention like rapamy that slows aging, it can impact all of the hallmarks. Um, and so I don't really I think those are like outputs or ways you can look at aging, but they're not that nobody is really just targeted.
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.